Amgen’s Parsabiv receives EC approval in secondary hyperparathyroidism

Amgen Inc., a leading American biopharmaceutical company, has achieved a significant milestone with the approval of its drug Parsabiv (etelcalcetide) by the European Commission (EC) ... Read More